viewAgile Therapeutics

Agile Therapeutics boosts executive team ahead of big year for Twirla

The biotech added healthcare veteran Kimberly Whelan as vice president market access

Agile Therapeutics -
Twirla has a PDUFA goal date of February 16, 2020

Agile Therapeutics Inc (NASDAQ:AGRX) is gearing up for the commercialization of its lead drug Twirla with some new faces on its executive team. 

The Princeton, New Jersey-based company has hired healthcare veteran Kimberly Whelan to take the role of vice president of market access, it announced Thursday. 

The role will see Whelan spearheading the development and execution of Agile’s market access strategy ahead of a number of key milestones for Twirla in 2020. 

READ: Agile Therapeutics wins FDA review extension of NDA for Twirla contraceptive

Twirla, which is an investigational, once-weekly combined hormonal contraceptive patch containing ethinyl estradiol and levonorgestrel, has a PDUFA date of February 16, 2020, whereby the US Food and Drug Administration must review Agile’s new drug application.

Whelan brings to the team over 35 years of experience in various capacities in the healthcare industry, such as finance, sales, marketing, business development and managed markets.

Agile also named Charles Grass as senior director, finance and Matthew Riley as product manager.

The company’s chief said in a statement that the biotech firm is excited for FDA approval.

“We remain focused on seeking FDA approval of Twirla and building a robust women’s health company,” said Al Altomari, Agile’s CEO. “We continue to make strategic investments and build our team to achieve those goals.”

The company's stock recently traded up 17.6% to $2.94 a share.

--ADDS stock price--

Contact Angela at angela@proactiveinvestors.com 

Follow her on Twitter @AHarmantas 

Quick facts: Agile Therapeutics


Price: 1.015 USD

Market Cap: $94.39 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Agile Therapeutics commercially launches its women's contraceptive patch...

Agile Therapeutics, Inc. (NASDAQ:AGRX) CEO Al Altomari tells Proactive the Princeton, New Jersey-based women’s healthcare company has commercially launched its low-dose, non-daily contraceptive patch for women named Twirla. Altomari says the group has built a system that can adapt to business...

on 12/09/2020

2 min read